BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29476499)

  • 1. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
    Winzenborg I; Nader A; Polepally AR; Liu M; Degner J; Klein CE; Mostafa NM; Noertersheuser P; Ng J
    Clin Pharmacokinet; 2018 Oct; 57(10):1295-1306. PubMed ID: 29476499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
    Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
    Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
    Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
    J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
    Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
    Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elagolix: First Global Approval.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
    Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
    N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
    Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
    Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
    J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
    Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
    Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
    Stodtmann S; Nader A; Polepally AR; Suleiman AA; Winzenborg I; Noertersheuser P; Ng J; Mostafa NM; Shebley M
    Clin Transl Sci; 2021 Jul; 14(4):1611-1619. PubMed ID: 33963686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
    Chiney MS; Ng J; Gibbs JP; Shebley M
    Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
    Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
    Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients.
    Abrao MS; Surrey E; Gordon K; Snabes MC; Wang H; Ijacu H; Taylor HS
    BMC Womens Health; 2021 Jun; 21(1):246. PubMed ID: 34134684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
    Abbas Suleiman A; Nader A; Winzenborg I; Beck D; Polepally AR; Ng J; Noertersheuser P; Mostafa NM
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):639-648. PubMed ID: 32945631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
    Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
    Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal Women.
    Chen MJ; Marroum P; Chiu YL; Neenan M; Mostafa NM; Shebley M
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):601-610. PubMed ID: 38593267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
    Ezzati M; Carr BR
    Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials.
    Surrey ES; Soliman AM; Palac HL; Agarwal SK
    Patient; 2019 Dec; 12(6):651-660. PubMed ID: 31654294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix.
    Agarwal SK; Soliman AM; Pokrzywinski RM; Snabes MC; Coyne KS
    J Sex Med; 2020 Dec; 17(12):2427-2433. PubMed ID: 32928659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials.
    Pokrzywinski RM; Soliman AM; Chen J; Snabes M; Diamond MP; Surrey E; Coyne KS
    Fertil Steril; 2019 Sep; 112(3):545-551. PubMed ID: 31227284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.